


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.



1. Issuer's Identity

CIK (Filer ID Number) 0001501756 Previous Name(s) [X] None Entity Type [X] Corporation [] Limited Partnership [] Limited Liability Company [] General Partnership [] Business Trust [] Other Name of Issuer Avalanche Biotechnologies, Inc. Jurisdiction of Incorporation/Organization DELAWARE Year of Incorporation/Organization [X] Over Five Years Ago [] Within Last Five Years (Specify Year) [] Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer Avalanche Biotechnologies, Inc. Street Address 1 665 Third Street, Suite 250 Street Address 2 City San Francisco State/Province/Country CALIFORNIA ZIP/Postal Code 94107 Phone No. of Issuer 650-735-1324

3. Related Persons

Last Name Chalberg First Name Thomas Middle Name W. Street Address 1 c/o Avalanche Biotechnologies, Inc. Street Address 2 665 Third Street, Suite 250 City San Francisco State/Province/Country CALIFORNIA ZIP/Postal Code 94107 Relationship: [X] Executive Officer [X] Director [] Promoter Clarification of Response (if Necessary)

Last Name Blumenkranz First Name Mark Middle Name S. Street Address 1 c/o Avalanche Biotechnologies, Inc. Street Address 2 665 Third Street, Suite 250 City State/Province/Country ZIP/Postal Code

San Francisco CALIFORNIA 94107

Relationship: [] Executive Officer [x] Director [] Promoter

Clarification of Response (if Necessary)

Last Name: Schwarz First Name: Steven Middle Name: D.

Street Address 1: c/o Avalanche Biotechnologies, Inc. Street Address 2: 665 Third Street, Suite 250

City: San Francisco State/Province/Country: CALIFORNIA ZIP/Postal Code: 94107

Relationship: [] Executive Officer [x] Director [] Promoter

Clarification of Response (if Necessary)

4. Industry Group

- Agriculture, Banking & Financial Services, Business Services, Energy, Health Care, Manufacturing, Real Estate, Retailing, Restaurants, Technology, Travel, Other

5. Issuer Size

- Revenue Range: [] No Revenues, [] \$1 - \$1,000,000, [] \$1,000,001 - \$5,000,000, [] \$5,000,001 - \$25,000,000, [] \$25,000,001 - \$100,000,000, [] Over \$100,000,000, [x] Decline to Disclose, [] Not Applicable
Aggregate Net Asset Value Range: [] No Aggregate Net Asset Value, [] \$1 - \$5,000,000, [] \$5,000,001 - \$25,000,000, [] \$25,000,001 - \$50,000,000, [] \$50,000,001 - \$100,000,000, [] Over \$100,000,000, [] Decline to Disclose, [] Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

- Rule 504(b)(1) (not (i), (ii) or (iii))
- Rule 504 (b)(1)(i)
- Rule 504 (b)(1)(ii)
- Rule 504 (b)(1)(iii)
- Rule 505
- Rule 506(b)
- Rule 506(c)
- Securities Act Section 4(a)(5)
- Investment Company Act Section 3(c)

7. Type of Filing

- New Notice Date of First Sale First Sale Yet to Occur
- Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes No

9. Type(s) of Securities Offered (select all that apply)

- Pooled Investment Fund Interests
- Equity
- Tenant-in-Common Securities
- Debt
- Mineral Property Securities
- Option, Warrant or Other Right to Acquire Another Security
- Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
- Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes No

Clarification of Response (if Necessary)

11. Minimum Investment

Minimum investment accepted from any outside investor \$ USD

12. Sales Compensation

Recipient <input type="text"/>	Recipient CRD Number <input checked="" type="checkbox"/> None	
(Associated) Broker or Dealer <input checked="" type="checkbox"/> None	(Associated) Broker or Dealer CRD Number <input checked="" type="checkbox"/> None	
Street Address 1 <input type="text"/>	Street Address 2 <input type="text"/>	
City <input type="text"/>	State/Province/Country <input type="text"/>	ZIP/Postal Code <input type="text"/>
State(s) of Solicitation <input type="text"/>	<input type="checkbox"/> All States	

13. Offering and Sales Amounts

Total Offering Amount \$ USD Indefinite
Total Amount Sold \$ USD
Total Remaining to be Sold \$ USD Indefinite

Clarification of Response (if Necessary)

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$ USD Estimate

Finders' Fees \$ USD Estimate

Clarification of Response (if Necessary)

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ USD Estimate

Clarification of Response (if Necessary)

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of

business or any State in which this notice is filed.

- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Avalanche Biotechnologies, Inc.	/s/ Thomas W. Chalberg	Thomas W. Chalberg, Ph.D.	President & Chief Executive Officer	2013-11-22